The effects of vosaroxin on cell viability were assessed in 13 human glioma cell lines and three patient-derived glioblastoma stem cell lines scored for MGMT, p53, and PTEN status (Table 1, Figure 2A). This evidence concerns the gene PTEN and central nervous system cancer.